866837-96-9

Basic information

• Product Name: Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate
• Synonyms: ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate;5-Amino-1-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester
• CAS NO: 866837-96-9
• Molecular Formula: C₁₂H₁₃N₃O₂
• Molecular Weight: 231.25
• Product Categories: Pyrazole
• Mol File: 866837-96-9.mol

Chemical Properties

• Boiling Point: 413 °C at 760 mmHg
• Flash Point: 203.6 °C
• Appearance: /
• Density: 1.25 g/cm³
• Vapor Pressure: 4.96E-07mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate(866837-96-9)
• EPA Substance Registry System: Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate(866837-96-9)

Safety Data

• Hazardous Substances Data: 866837-96-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate is used as a key intermediate in the synthesis of various drugs and bioactive molecules. Its unique chemical structure allows for the development of new chemical entities with potential therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate serves as a valuable building block for the synthesis of more complex molecules. Its versatile reactivity and functional groups enable the formation of a wide range of compounds with diverse applications.
Used in Anti-inflammatory Applications:
Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate has shown potential anti-inflammatory properties in experimental studies. It can be used as an active pharmaceutical ingredient in the development of new drugs for the treatment of various inflammatory conditions.
Used in Analgesic Applications:
Due to its analgesic properties, Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate can be employed in the formulation of pain-relieving medications. Its ability to alleviate pain makes it a promising candidate for the development of new analgesic drugs.
Used in Antipyretic Applications:
Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate has demonstrated antipyretic properties, making it suitable for the development of new antipyretic drugs. These drugs can help in reducing fever and associated symptoms in patients.
Used in Agrochemicals Production:
In addition to its applications in the pharmaceutical industry, Ethyl 5-amino-1-phenyl-1H-pyrazole-3-carboxylate can also serve as an intermediate in the production of agrochemicals. Its unique chemical properties can be utilized in the synthesis of bioactive compounds for agricultural applications, such as pesticides and herbicides.

InChI:InChI=1/C12H13N3O2/c1-2-17-12(16)10-8-11(13)15(14-10)9-6-4-3-5-7-9/h3-8H,2,13H2,1H3

Upstream product

• 59-88-1 phenylhydrazine hydrochloride 
• 64-17-5 ethanol 
• 92664-05-6 potassium 1-cyano-3-ethoxy-3-oxoprop-1-en-2-olate 
• 100-63-0 phenylhydrazine 

Downstream Products

• 866838-11-1 1-phenyl-5-[3-benzoyl-thioureido]-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1015765-50-0 C₁₆H₁₅N₃O₂ 
• 1391944-38-9 5-(2,2-Dimethyl-propionylamino)-1-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1053164-76-3 5-amino-1-phenyl-1H-pyrazole-3-carboxylic acid 
• 1391943-01-3 (S)-3-[(5-amino-1-phenyl-1H-pyrazole-3-carbonyl)amino]-3-(o-tolyl)propionic acid 
• 1279037-47-6 (S)-3-{[5-((cyclopropylmethyl)amino)-1-phenyl-1H-pyrazole-3-carbonyl]amino}-3-(o-tolyl)propionic acid 
• 1279037-44-3 (S)-3-{[5-(bis-(cyclopropylmethyl)-amino)-1-phenyl-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid 
• 1391944-27-6 1-phenyl-5-pyrrolidin-1-yl-1H-pyrazole-3-carboxylic acid 
• 1391944-30-1 1-Phenyl-5-(3-phenyl-ureido)-1H-pyrazole-3-carboxylic acid 
• 1391944-32-3 5-methanesulfonylamino-1-phenyl-1H-pyrazole-3-carboxylic acid 
• 1391944-34-5 5-(2-oxo-pyrrolidin-1-yl)-1-phenyl-1H-pyrazole-3-carboxylic acid 
• 1391944-36-7 1-phenyl-5-(pyridin-2-ylamino)-1H-pyrazole-3-carboxylic acid 
• 1391944-57-2 5-((cyclopropylmethyl)amino)-1-phenyl-1H-pyrazole-3-carboxylic acid 
• 1391944-59-4 5-(bis-(cyclopropyl-methyl)-amino)-1-phenyl-1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Diazole-pyrazolecarboxamide derivative and microwave hydrothermal synthesis method and application thereof

The invention relates to the technical field of organic synthesis, in particular to a N-(5-[1,3,4]diazole-2-yl-2H-pyrazole-3-yl)-carboxamide derivative and a microwave hydrothermal synthesis method thereof, and further relates to application of the compound. A series of basic raw materials such as amine, 2,3-dicyan-opropionate, alcohol, acyl halide and the like are used for synthetizing of pyrazolecarbonitrile, pyrazolecarbonitrile is subjected to esterification, hydrazide reaction and amidation and reacts with a cyclization agent by the microwave hydrothermal synthesis method so as to obtainN-(5-[1,3,4]diazole-2-yl-2H-pyrazole-3-yl)-carboxamide derivative (including thiadiazole and oxadiazole). The derivative has good biological activity, can inhibit various bacterial stains, and has high activity in terms of bacterial resistance and insect killing; in terms of chemical structure, the derivative, according with the general formula, is synthetized, has great variety of active groups and excellent photo-physical properties, has multiple functions in the fields such as photoelectricity, medicines, pesticides, bacteriostat, diminish inflammation and virus protection, and accordinglyhas high development and application value.

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors

Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals The present invention relates to compounds of the formula (I), wherein A, D, E, G, R10 R11, R30 R40 R50

AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R11, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides

The new 1-phenyl-5-(1H-pyrrol-1-yl)pyrazole-3-carboxamides were compared with the reference compounds AM251 and SR144528 for cannabinoid hCB1 and hCB2 receptor affinity. Compounds bearing 2,4-dichlorophenyl or 2,4-difluorophenyl groups at position 1 and 2,5-dimethylpyrrole moiety at position 5 of the pyrazole nucleus were generally more selective for hCB 1. On the other hand, the N-cyclohexyl group at the 3-carboxamide was the determinant for the hCB2 selectivity, in particular when a 3,4-dichlorophenyl group was also present at position 1. Compound 26 was the most selective ligand for the hCB1 receptor (Ki (CB 2)/Ki (CB1) = 140.7). Derivative 30, the most potent hCB1 ligand (Ki = 5.6 nM), was equipotent to AM251 and behaved as an inverse agonist in the cAMP assay (EC50 ～1 nM). The carbonyl oxygen of both 26 and 30 formed a H-bond with K3.28(192), while the substituents at the nitrogen fitted in a pocket formed by lipophilic residues. This H-bonding interaction was proposed to account for the high affinity for receptors' inactive state and the inverse agonist activity.

Preparation and optimization of a series of 3-carboxamido-5- phenacylaminopyrazole bradykinin B1 receptor antagonists

The B1 receptor is an attractive target for the treatment of pain and inflammation. A series of 3-carboxamido-5-phenacylamino pyrazole B1 receptor antagonists are described that exhibit good potency against B1 and high selectivity over B2. Initially, N-un

NOVEL THIAZOLOPYRAZOLES AND METHODS OF THEIR USE

This invention concerns novel thiazolopyrazole compounds of formula (I) and compositions comprising them. Methods of using these compounds for the treatment, prevention and management of various diseases and disorders are also encompassed by the invention.

4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.